ETTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Entasis Therapeutics Holdings's land and improvements for the quarter that ended in Mar. 2022 was $0.00 Mil.
The historical data trend for Entasis Therapeutics Holdings's Land And Improvements can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entasis Therapeutics Holdings Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Land And Improvements | Get a 7-Day Free Trial | - | - | - | - | - |
Entasis Therapeutics Holdings Quarterly Data | ||||||||||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Land And Improvements | Get a 7-Day Free Trial | - | - | - | - | - |
Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.
Theravance Inc | 10 percent owner | 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010 |
Kristie Ann Wagner | officer: VP, Principal Fin & Acct Off | 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
David Altarac | officer: Chief Medical Officer | 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Michael Gutch | officer: Chief Fin. and Bus. Officer | C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
John Patrick Mueller | officer: Chief Development Officer | C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Manoussos Perros | director, officer: President and CEO | C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Ruben Tommasi | officer: Chief Scientific Officer | C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Matthew Ronsheim | officer: See Remarks | 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Elizabeth M Keiley | officer: General Counsel | C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Anna Diaz Triola | officer: Chief Commercial Officer | 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Innoviva Strategic Opportunities Llc | director, 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
Eric Wilson Kimble | officer: Chief Commercial Officer | C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Howard Mayer | director | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Heather Behanna | director | C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451 |
From GuruFocus
By PurpleRose PurpleRose • 07-12-2022
By PRNewswire PRNewswire • 07-03-2022
By PRNewswire PRNewswire • 06-23-2022
By GuruFocusNews GuruFocusNews • 06-23-2022
By PRNewswire PRNewswire • 07-07-2022
By PurpleRose PurpleRose • 07-13-2022
By PRNewswire PRNewswire • 07-13-2022
By PRNewswire PRNewswire • 07-04-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.